Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (22)
  • Open Access

    ARTICLE

    LncRNA AFAP1-AS1 exhibits oncogenic characteristics and promotes gemcitabine-resistance of cervical cancer cells through miR-7-5p/EGFR axis

    CHAOQUN WANG1, TING ZHANG2, CHAOHE ZHANG3,*

    Oncology Research, Vol.32, No.12, pp. 1867-1879, 2024, DOI:10.32604/or.2024.044547 - 13 November 2024

    Abstract Background: Drug resistance is the main factor contributing to cancer recurrence and poor prognosis. Exploration of drug resistance-related mechanisms and effective therapeutic targets are the aim of molecular targeted therapy. In our study, the role of long non-coding RNA (lncRNA) AFAP1-AS1 in gemcitabine resistance and related mechanisms were explored in cervical cancer cells. Methods: Gemcitabine-resistant cervical cancer cell lines HT-3-Gem and SW756-Gem were constructed using the gemcitabine concentration gradient method. The overall survival rates and recurrence-free survival rates were evaluated by Kaplan-Meier analysis. The interaction was verified through a Dual-luciferase reporter gene assay and a… More > Graphic Abstract

    LncRNA AFAP1-AS1 exhibits oncogenic characteristics and promotes gemcitabine-resistance of cervical cancer cells through miR-7-5p/EGFR axis

  • Open Access

    ARTICLE

    Piperlongumine in combination with EGFR tyrosine kinase inhibitors for the treatment of lung cancer cells

    SHAIL RAKESH MODI, TERRICK ANDEY*

    Oncology Research, Vol.32, No.11, pp. 1709-1721, 2024, DOI:10.32604/or.2024.053972 - 16 October 2024

    Abstract Objectives: EGFR tyrosine kinase inhibitor (EGFR-TKI) therapies such as erlotinib and gefitinib are approved for the treatment of non-small cell lung cancer (NSCLC). However, the high incidence of acquired resistance to these EGFR-TKIs may preclude their effectiveness. Piperlongumine (PPL), an extract from the long pepper fruit (Piper longum), has been shown to possess anticancer properties. The purpose of the study was to investigate piperlongumine as an anticancer agent and to study a combination treatment approach with EGFR-TKIs against lung cancer cells. Methods: Anticancer efficacy of PPL, erlotinib (ERL), gefitinib (GEF), and cisplatin (CIS) were investigated in… More >

  • Open Access

    ARTICLE

    Identification of TMEM159 as a biomarker of glioblastoma progression based on immune characteristics

    JI SHI1,2, YE ZHANG2, YI CHEN2, TANGJUN GUO3,*, HAOZHE PIAO2,*

    BIOCELL, Vol.48, No.8, pp. 1241-1263, 2024, DOI:10.32604/biocell.2024.051049 - 02 August 2024

    Abstract Background: Glioblastoma multiforme (GBM) is the most general malignancy of the primary central nervous system that is characterized by high aggressiveness and lethality. Transmembrane protein 159 (TMEM159) is an endoplasmic reticulum protein that can form oligomers with seipin. The TMEM159-seipin complex decides the site of lipid droplet (LD) formation, and the formation of LDs is a marker of GBM. However, the role of TMEM159 in the progression of GBM has not been investigated to date. Methods: In this study, we examined the genes that may be associated with patient prognosis in GBM by bioinformatics analyses,… More >

  • Open Access

    ARTICLE

    Knockdown of HE4 suppresses tumor growth and invasiveness in lung adenocarcinoma through regulation of EGFR signaling

    YUE ZHANG1,#, WENYU YANG1,#, XIAOWANG HAN1,#, YUE QIAO1, HAITAO WANG2, TING CHEN1, TIANYING LI1, WEN-BIN OU1,*

    Oncology Research, Vol.32, No.6, pp. 1119-1128, 2024, DOI:10.32604/or.2024.045025 - 23 May 2024

    Abstract It has been shown that the high expression of human epididymis protein 4 (HE4) in most lung cancers is related to the poor prognosis of patients, but the mechanism of pathological transformation of HE4 in lung cancer is still unclear. The current study is expected to clarify the function and mechanism of HE4 in the occurrence and metastasis of lung adenocarcinoma (LUAD). Immunoblotting evaluated HE4 expression in lung cancer cell lines and biopsies, and through analysis of The Cancer Genome Atlas (TCGA) dataset. Frequent HE4 overexpression was demonstrated in LUAD, but not in lung squamous… More >

  • Open Access

    ARTICLE

    Circ_0053943 complexed with IGF2BP3 drives uveal melanoma progression via regulating N6-methyladenosine modification of Epidermal growth factor receptor

    ANDI ZHAO1,2,#, YUE WANG3,#, ZIJIN WANG1,2, QING SHAO1,2, QI GONG1,2, HUI ZHU1,2, SHIYA SHEN1,2, HU LIU1,2,*, XUEJUAN CHEN1,2,*

    Oncology Research, Vol.32, No.5, pp. 983-998, 2024, DOI:10.32604/or.2024.045972 - 23 April 2024

    Abstract Numerous studies have characterized the critical role of circular RNAs (circRNAs) as regulatory factors in the progression of multiple cancers. However, the biological functions of circRNAs and their underlying molecular mechanisms in the progression of uveal melanoma (UM) remain enigmatic. In this study, we identified a novel circRNA, circ_0053943, through re-analysis of UM microarray data and quantitative RT-PCR. Circ_0053943 was found to be upregulated in UM and to promote the proliferation and metastatic ability of UM cells in both in vitro and in vivo settings. Mechanistically, circ_0053943 was observed to bind to the KH1 and KH2 domains of insulin-like… More > Graphic Abstract

    <i>Circ_0053943</i> complexed with IGF2BP3 drives uveal melanoma progression via regulating N6-methyladenosine modification of <i>Epidermal growth factor receptor</i>

  • Open Access

    ARTICLE

    High-throughput computational screening and in vitro evaluation identifies 5-(4-oxo-4H-3,1-benzoxazin-2-yl)-2-[3-(4-oxo-4H-3,1-benzoxazin-2-yl) phenyl]-1H-isoindole-1,3(2H)-dione (C3), as a novel EGFR—HER2 dual inhibitor in gastric tumors

    MESFER AL SHAHRANI, REEM GAHTANI, MOHAMMAD ABOHASSAN, MOHAMMAD ALSHAHRANI, YASSER ALRAEY, AYED DERA, MOHAMMAD RAJEH ASIRI, PRASANNA RAJAGOPALAN*

    Oncology Research, Vol.32, No.2, pp. 251-259, 2024, DOI:10.32604/or.2023.043139 - 28 December 2023

    Abstract Gastric cancers are caused primarily due to the activation and amplification of the EGFR or HER2 kinases resulting in cell proliferation, adhesion, angiogenesis, and metastasis. Conventional therapies are ineffective due to the intra-tumoral heterogeneity and concomitant genetic mutations. Hence, dual inhibition strategies are recommended to increase potency and reduce cytotoxicity. In this study, we have conducted computational high-throughput screening of the ChemBridge library followed by in vitro assays and identified novel selective inhibitors that have a dual impediment of EGFR/HER2 kinase activities. Diversity-based High-throughput Virtual Screening (D-HTVS) was used to screen the whole ChemBridge small molecular… More > Graphic Abstract

    High-throughput computational screening and <i>in vitro</i> evaluation identifies 5-(4-oxo-4H-3,1-benzoxazin-2-yl)-2-[3-(4-oxo-4H-3,1-benzoxazin-2-yl) phenyl]-1H-isoindole-1,3(2H)-dione (C3), as a novel EGFR—HER2 dual inhibitor in gastric tumors

  • Open Access

    ARTICLE

    Glucocorticoid reduces the efficacy of afatinib on the head and neck squamous cell carcinoma

    DONGYANG WANG, YI CHEN, JING HUANG, YOU ZHANG, CHONGKUI SUN, YINGQIANG SHEN*

    BIOCELL, Vol.47, No.2, pp. 329-338, 2023, DOI:10.32604/biocell.2023.023489 - 18 November 2022

    Abstract Glucocorticoids (GC) are widely used to counter the adverse events during cancer therapy; nonetheless, previous studies pointed out that GC may reduce the efficacy of chemotherapy on cancer cells, especially in epidermal growth factor receptor (EGFR)-targeted therapy of head and neck squamous cell carcinoma (HNSCC) remaining to be elucidated. The primary aim of the present study was to probe into the GC-induced resistance of EGFR-targeted drug afatinib and the underlying mechanism. HNSCC cell lines (HSC-3, SCC-25, SCC-9, and H-400) and the human oral keratinocyte (HOK) cell lines were assessed for GC receptor (GR) expression. The… More >

  • Open Access

    ARTICLE

    MiR-21/Sonic Hedgehog (SHH)/PI3K/AKT Pathway is Associated with NSCLC of Primary EGFR-TKI Resistance

    Li Xu, Kang Li, Jia Li, Liyu Liu, Fang Xu, Yan Xu, Yi Kong, Xingxiang Pu, Qianzhi Wang, Jingyi Wang, Bolin Chen*, Lin Wu*

    Oncologie, Vol.24, No.3, pp. 579-590, 2022, DOI:10.32604/oncologie.2022.022121 - 19 September 2022

    Abstract Background: Non-small cell lung cancer (NSCLC), caused by abnormal gene drive, may have primary drug resistance after treatment with tyrosine kinase inhibitors (EGFR-TKIs). Therefore, we explore whether the primary drug-resistant NSCLC treated with EGFR-TKI is related to the miR-21/Sonic Hedgehog (SHH)/PI3K/AKT pathway. Methods: The patients from our hospital who meet the AJCC TNM staging (7th edition) stage IIIB and stage IV NSCLC were selected in this case study. Thereafter, the treatment response of EGFR-TKIs was evaluated according to the solid tumor efficacy evaluation standard (version 1.1). The patients were divided into the EGFR-TKIs primary drug resistance group… More >

  • Open Access

    REVIEW

    Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations

    Yudie Yang*1, Xia Zhang†1, Yajie Gao*, Yan Dong*, Di Wang*, Yanping Huang*, Tianhao Qu*, Buqun Fan*, Qizheng Li*, Chunxia Zhang*, Xiaonan Cui*, Bin Zhang*

    Oncology Research, Vol.29, No.1, pp. 63-74, 2021, DOI:10.3727/096504022X16462176651719

    Abstract Lung cancer is a malignant tumor with high incidence and mortality across the world. The use of immune checkpoint inhibitors for lung cancer has improved the prognosis of some lung cancer patients to a greater extent and provided a new direction for the clinical treatment of lung cancer. Immunotherapy still has limitations in terms of its appropriate population and adverse reactions. Particularly for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation, there has been no major breakthrough in current immunotherapy. Whether immunotherapy can bring new benefits after drug resistance is More >

  • Open Access

    ARTICLE

    Thymidylate synthase confers pemetrexed resistance of non-small cell lung cancer cells by EGFR/PI3K/AKT pathway

    DAN ZHANG1, HAIJING LIU1, ZHENNAN YI2, YUANYUAN LU3, YANYAN CHEN4, WEIQIANG SU2, HUIBING LIN2, ZHIHUI ZHANG5,*, WEI LEI6,*

    BIOCELL, Vol.45, No.3, pp. 617-625, 2021, DOI:10.32604/biocell.2021.012504 - 03 March 2021

    Abstract Chemotherapy drug resistance is the main cause leading to the relapse and metastasis of non-small cell lung cancer (NSCLC) patients. Our study aimed to investigate the mechanism of pemetrexed resistance in NSCLC. Firstly, the pemetrexed (PEM)-resistant PC-9 and A549 lung adenocarcinoma cell lines (PC-9/PEM and A549/PEM) were established. The expression of thymidylate synthase (TS) in PC-9/PEM, A549/PEM, A549, and PC-9 cells were analyzed by qRT-PCR and western blot. Then, cell viability, colony formation, migration, and invasion were performed on PEM-resistant cells transfected with TS siRNA. The role of EGFR in PEM resistance of PEM-resistant cells… More >

Displaying 1-10 on page 1 of 22. Per Page